Netherlands· NL-d3fc0813da72
Jemperli 500 mg oplossing voor infusie
A dostarlimab product containing dostarlimab, registered in Netherlands by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Dostarlimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF07 (dostarlimab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Dostarlimab · ATC L01FF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- DOSTARLIMAB
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Netherlands (NL)
- ATC code
- L01FF07
- ATC class
- Dostarlimab
- Defined daily dose
- 24 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1538
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJEMPERLIGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- SwitzerlandJemperli
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- FranceJEMPERLI 500 mg, solution à diluer pour perfusionGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- United KingdomJemperli 500mg/10ml concentrate for solution for infusion vialsGlaxoSmithKline UK Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- IcelandJemperliGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4e31c64c-e2eb-49e5-bdcd-71a0ce4b481b GET /v1/drugs/4e31c64c-e2eb-49e5-bdcd-71a0ce4b481b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Dostarlimab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126463",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"CITROENZUUR 1-WATER (E 330)",
"NATRIUMCHLORIDE",
"POLYSORBAAT 80 (E 433)",
"STIKSTOF (HEAD SPACE) (E 941)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"DOSTARLIMAB"
],
"leaflet_url": null,
"authorised_at": "2021/04/21",
"procedure_number": "EMEA/H/C/005204",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1538",
"additional_monitoring": "Y"
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.